10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Global measles elimination

      review-article
      1 , 2 , 2 ,
      Nature Reviews. Microbiology
      Nature Publishing Group UK

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          • Measles remains a leading vaccine-preventable cause of child mortality in Africa and Asia, and continues to cause outbreaks in industrialized countries.

          • Remarkable progress in reducing measles incidence and mortality has been made in resource-poor countries, particularly in sub-Saharan Africa, as a consequence of increasing measles vaccine coverage and provision of a second opportunity for measles vaccination through supplementary immunization activities.

          • Measles virus (MV) is highly infectious, requiring a high level of population immunity to interrupt transmission, and might be more difficult to eliminate in regions of high population density and high prevalence of human immunodeficiency virus type 1 (HIV-1) infection.

          • The global elimination of measles has been debated since the 1960's, shortly after measles vaccines were first licensed.

          • Criteria necessary for disease eradication include: first, humans must be required for virus transmission; second, sensitive and specific diagnostic tools must exist; and finally an effective intervention must be available. Measles is thought by many experts to meet all of these criteria

          • Measles vaccines are safe, effective and have interrupted MV transmission in large geographic areas, providing a suitable tool for global measles elimination.

          • The ideal measles vaccine would be inexpensive, safe, heat-stable, immunogenic in neonates or very young infants, administered as a single dose without needle or syringe, and would not prime individuals for atypical measles or be associated with prolonged immunosuppression. Several vaccine candidates with some of these characteristics are undergoing development.

          • A significant challenge to global measles elimination efforts will be to maintain the resources, political will and public confidence to implement measles vaccination and surveillance programmes.

          Abstract

          Safe and effective vaccines are available that could be used to eradicate measles, which is a primary cause of childhood vaccine-preventable deaths worldwide. This article reviews the pathogenesis of this deadly disease and the prospects for its elimination.

          Abstract

          Measles remains a leading vaccine-preventable cause of child mortality worldwide, particularly in sub-Saharan Africa where almost half of the estimated 454,000 measles deaths in 2004 occurred. However, great progress in measles control has been made in resource-poor countries through accelerated measles-control efforts. The global elimination of measles has been debated since measles vaccines were first licensed in the 1960's, and this debate is likely to be renewed if polio virus is eradicated. This review discusses the pathogenesis of measles and the likelihood of the worldwide elimination of this disease.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          Individual and community risks of measles and pertussis associated with personal exemptions to immunization.

          The risk of vaccine-preventable diseases among children who have philosophical and religious exemptions from immunization has been understudied. To evaluate whether personal exemption from immunization is associated with risk of measles and pertussis at individual and community levels. Population-based, retrospective cohort study using data collected on standardized forms regarding all reported measles and pertussis cases among children aged 3 to 18 years in Colorado during 1987-1998. Relative risk of measles and pertussis among exemptors and vaccinated children; association between incidence rates among vaccinated children and frequency of exemptors in Colorado counties; association between school outbreaks and frequency of exemptors in schools; and risk associated with exposure to an exemptor in measles outbreaks. Exemptors were 22.2 times (95% confidence interval [CI], 15.9-31.1) more likely to acquire measles and 5.9 times (95% CI, 4.2-8.2) more likely to acquire pertussis than vaccinated children. After adjusting for confounders, the frequency of exemptors in a county was associated with the incidence rate of measles (relative risk [RR], 1.6; 95% CI, 1.0-2.4) and pertussis (RR, 1.9; 95% CI, 1.7-2.1) in vaccinated children. Schools with pertussis outbreaks had more exemptors (mean, 4.3% of students) than schools without outbreaks (1. 5% of students; P =.001). At least 11% of vaccinated children in measles outbreaks acquired infection through contact with an exemptor. The risk of measles and pertussis is elevated in personal exemptors. Public health personnel should recognize the potential effect of exemptors in outbreaks in their communities, and parents should be made aware of the risks involved in not vaccinating their children.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Measles endemicity in insular populations: critical community size and its evolutionary implication.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months.

              Measles causes serious morbidity in infants, with the highest risk among those who are 6 to 12 months of age. In the United States, measles vaccine has been given at age 12 to 15 months to minimize interference by passive antibodies and to achieve the high seroprevalence required for herd immunity. Infants of mothers with vaccine-induced immunity may lose passively acquired antibodies before 12 months, leaving them susceptible to measles infection. To assess the immunogenicity of measles vaccine in infants younger than 12 months. Cohort study conducted before and after measles immunization. Pediatric clinic in Palo Alto, Calif. Infants 6 (n = 27), 9 (n = 26), and 12 (n = 34) months of age were enrolled; 72 provided both initial and follow-up samples. Evaluation of immunogenicity before and 12 weeks after measles vaccination, including measles neutralizing antibody titers, measles-specific T-cell proliferation, and cytokine profiles. Measles neutralizing antibodies were present before vaccination in 52% (12/23), 35% (7/20), and 0% (0/22) of 6-, 9-, and 12-month-old infants, respectively. In the absence of detectable passive antibodies, geometric mean titers after vaccination were significantly lower in 6-month-old infants compared with 9-month-old infants (27 vs 578, P = .01) and 12-month-old infants (27 vs 972, P=.001). The seroconversion rate, defined as a 4-fold rise in antibody titer, in these 6-month-old infants was only 67%, and only 36% of these infants achieved seroprotective neutralizing antibody titers of 120 or higher after vaccination compared with 100% of 9- and 12-month-old infants lacking detectable passive antibody prior to vaccination. T-cell proliferation and cytokine responses to measles did not differ with age. Humoral immunity was deficient in 6-month-old infants given measles vaccine, even in the absence of detectable passively acquired neutralizing antibodies. Comparison of their responses with those of 9- and 12-month-old infants indicates that a developmental maturation of the immune response to measles may occur during the first year of life, which affects the immunogenicity of measles vaccine.
                Bookmark

                Author and article information

                Contributors
                dgriffin@jhsph.edu
                Journal
                Nat Rev Microbiol
                Nat. Rev. Microbiol
                Nature Reviews. Microbiology
                Nature Publishing Group UK (London )
                1740-1526
                1740-1534
                6 November 2006
                2006
                : 4
                : 12
                : 900-908
                Affiliations
                [1 ]GRID grid.21107.35, ISNI 0000 0001 2171 9311, Department of Epidemiology, , Johns Hopkins University, Bloomberg School of Public Health, ; Baltimore, 21205 Maryland USA
                [2 ]GRID grid.21107.35, ISNI 0000 0001 2171 9311, W. Harry Feinstone Department of Molecular Microbiology and Immunology, , Johns Hopkins University, Bloomberg School of Public Health, ; Baltimore, 21205 Maryland USA
                Article
                BFnrmicro1550
                10.1038/nrmicro1550
                7097605
                17088933
                0d582bb3-f513-4c7d-814d-0ce54a9f9bcf
                © Nature Publishing Group 2006

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2006

                Comments

                Comment on this article